WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007008848) MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/008848    International Application No.:    PCT/US2006/026809
Publication Date: 18.01.2007 International Filing Date: 07.07.2006
IPC:
A61K 39/395 (2006.01), A61K 38/00 (2006.01), C07K 2/00 (2006.01)
Applicants: SEATTLE GENETICS, INC. [US/US]; 21823 - 30th Dr. SE, Bothell, Washington 98021 (US) (For All Designated States Except US).
DORONINA, Svetlana O. [RU/US]; (US) (For US Only).
KLINE, Toni Beth [US/US]; (US) (For US Only).
JEFFREY, Scott [US/US]; (US) (For US Only).
SENTER, Peter D. [US/US]; (US) (For US Only).
MEYER, Damon [US/US]; (US) (For US Only)
Inventors: DORONINA, Svetlana O.; (US).
KLINE, Toni Beth; (US).
JEFFREY, Scott; (US).
SENTER, Peter D.; (US).
MEYER, Damon; (US)
Priority Data:
60/697,728 07.07.2005 US
Title (EN) MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS
(FR) COMPOSES DE MONOMETHYLVALINE PRESENTANT DES MODIFICATIONS CARBOXY PHENYLALANINE A LA TERMINAISON C
Abstract: front page image
(EN)Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
(FR)L'invention concerne des analogues de peptides d'auristatine de MeVal-Val-Dil-Dap-Phe (MMAF) ayant un acide carboxylique équivalent à la phénylalanine C-terminale que l'on prépare et que l'on fixe à des ligands par divers lieurs, y compris le maléimidocaproyl-val-cit-PAB. Les conjugués médicament ligand obtenus ont présentés une activité in vitro et in vivo.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)